Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
Development of cell-free protein synthesis platforms for discovery and/or production of biologicals is a funding call from European Commission – Horizon Europe that closes 17 February 2027 (forthcoming — not yet open). Funding: EUR 6,000,000–8,000,000 per project. Eligibility: Collaborative Horizon Europe project: legal entities in EU Member States or associated countries, normally as a consortium (standard Horizon Europe eligibility, Annex B). Status: forthcoming — submission not yet open.
- Funder
- European Commission – Horizon Europe
- Deadline
- 17 Feb 2027 (125 days)
- Status
- Forthcoming
- Amount
- EUR 6,000,000–8,000,000 per project
- Region / eligibility
- EU Member States & Horizon Europe associated countries
- Career stage
- established / PI
- Fields
- chemistry, pharma process
- Reference
- HORIZON-HLTH-2027-01-IND-01
- Official call
- EU Funding & Tenders listing
Eligibility in plain language
Collaborative Horizon Europe project: legal entities in EU Member States or associated countries, normally as a consortium (standard Horizon Europe eligibility, Annex B). Status: forthcoming — submission not yet open.
Who should apply
Synthetic, physical and analytical chemists, medicinal chemists and pharma process / drug-development teams — best fit for PIs and research groups able to join or build a multi-country consortium.
Summary from source
Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Maintaining an innovative, sustainable, and competitive EU health industry”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: Biopharmaceutical industries get access to streamlined development and production processes for peptide- or protein-based biologicals. Health systems benefit from the availability of enhanced or decentralised production systems for innovative health technologies that involve peptides or proteins, and which improve health and care. Citizens and patients will benefit from better access, availability and affordability of pharmaceuticals based on biologicals. Scope: Cell-Free Protein Synthesis (CFPS) has been em…